Ernexa Nears IND Filing for ERNA-101, Advancing Towards First-in-Human Study

Ernexa announced it is advancing its lead therapeutic candidate, ERNA-101, toward a first-in-human (FIH) study, with an Investigational New Drug (IND) application filing nearing. This development marks a significant regulatory milestone for the company, potentially paving the way for clinical trials. The impending IND submission will provide the U.S. Food and Drug Administration (FDA) with comprehensive data on ERNA-101's safety and efficacy from preclinical studies. The drug candidate is designed to address [specific therapeutic area, if mentioned in the original article, otherwise keep general]. Moving to FIH studies is a critical step in drug development, allowing for initial safety and pharmacokinetic evaluations in human subjects. Ernexa's progress with ERNA-101 positions the company to potentially expand its clinical pipeline.